erlotinib hydrochloride has been researched along with Acne Vulgaris in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Yin, R; Yu, Y; Zou, Y | 1 |
| Aoyama, T; Ishikawa, H; Sato, J; Shikamura, Y; Shino, M; Tanaka, R | 1 |
| Dizdar, O; Gököz, O; Yalçin, B; Yalçin, S | 1 |
3 other study(ies) available for erlotinib hydrochloride and Acne Vulgaris
| Article | Year |
|---|---|
5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneform rash induced by erlotinib: A case report.
Topics: Acne Vulgaris; Aminolevulinic Acid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Photochemotherapy; Photosensitizing Agents; Skin Diseases | 2022 |
Prevention of Acne-Like Eruption Caused by Panitumumab Treatment through Oral Administration of Non-steroidal Anti-inflammatory Drugs.
Topics: Acne Vulgaris; Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Panitumumab; Quality of Life; Receptors, Growth Factor; Retrospective Studies | 2022 |
Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Topics: Acne Vulgaris; Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |